HLS Therapeutics Inc (TSE:HLS) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
HLS Therapeutics Inc. has announced a significant expansion in the availability of its cardiovascular drug Vascepa, with Alberta’s public drug plan now covering the medication. This expansion means that over 90% of Canadians with public or private insurance will have access to the drug for the secondary prevention of cardiovascular events. The company emphasizes the importance of addressing cardiovascular disease, a leading cause of death in Canada, by improving national coverage for Vascepa.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue